EDAP TMS SA
No enriched coverage for $EDAP in the last 7 days.
No SEC Form 4 filings for $EDAP in the last 30 days.
This document provides the transcript of the EDAP TMS SA Q1 2026 Earnings Call, held on May 7, 2026. The call details the company's financial and operating results for the first quarter of 2026. Louisa Smith from Gilmartin Group hosted the initial part of the conference call.
EDAP (Nasdaq: EDAP) reported record HIFU revenue of $11.6 million in Q1 2026, marking a 78% year-over-year increase, driven by an 83% rise in Focal One system sales and 53% growth in U.S. procedures. The company also announced international capital sales in the UK, France, and Hungary, where Focal One Robotic HIFU will be used for both prostate cancer and deep infiltrating endometriosis. Despite this growth, EDAP reported a net loss of $9.1 million for the quarter, but reiterated its 2026 HIFU revenue guidance of $50.0 million to $54.0 million.
EDAP TMS SA reported strong Q1 2026 revenue growth, reaching $17.8 million, largely driven by a 78% year-over-year increase in its High-Intensity Focused Ultrasound (HIFU) business, which generated $11.6 million. Despite an improved gross margin of 45.7%, the company experienced a wider net loss of $9.1 million, or $0.24 per share, due to higher operating expenses. EDAP reiterated its 2026 financial guidance, anticipating significant growth in HIFU revenue.
